{
  "abstract": "Abstract Overview of: Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet 2026;407(10529):689-703.",
  "authors": [
    {
      "affiliations": [],
      "name": "BMJ Publishing Group Ltd"
    }
  ],
  "title": "Statin labelling may overstate adverse events",
  "uid": "884d9830-b28f-5300-808f-7061e1a2988c"
}